Physician profile
Rahul Dev Kataria
NPI 1538401831
$10,368.04
in general payments reported to CMS, 2019-2025
30 companies · $2,023 in 2025
The $2,023 reported for 2025 was more than what 79% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.00 · 2020: $501 · 2021: $2,331 · 2022: $1,758 · 2023: $1,795 · 2024: $1,861 · 2025: $2,023.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,679.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,679.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,647.59 | 2020-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,173.33 | 2020-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $962.78 | 2019-2025 | Stelara, Tremfya |
| Celgene Corporation | $886.35 | 2021-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $795.38 | 2020-2025 | Entyvio, Gattex, Eohilia |
| Genzyme Corporation | $507.77 | 2022-2025 | |
| Qol Medical, LLC | $491.30 | 2020-2025 | Sucraid, Sucraid |
| Pfizer INC. | $395.32 | 2021-2025 | |
| Nestle Healthcare Nutrition INC. | $362.46 | 2020-2023 | |
| E.R. Squibb & Sons, L.L.C. | $317.69 | 2021-2023 | Zeposia |
| Celltrion USA INC. | $306.96 | 2024-2025 | Vegzelma, Zymfentra |
| Ferring Pharmaceuticals INC. | $174.13 | 2020-2024 | Rebyota |
| Braintree Laboratories, INC. | $161.25 | 2020-2023 | Sutab |
| Madrigal Pharmaceuticals | $141.69 | 2024-2025 | Rezdiffra, Resmetirom |
| Ipsen Biopharmaceuticals, INC | $133.58 | 2024-2025 | Iqirvo |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $125.00 | 2021 | |
| Daiichi Sankyo INC. | $125.00 | 2021 | |
| Ardelyx, INC. | $124.72 | 2022-2025 | Ibsrela |
| Ethicon US, LLC | $112.64 | 2025 | Linx Reflux Management System, Harmonic |
| Ironwood Pharmaceuticals, INC | $97.78 | 2021-2024 | |
| Novo Nordisk INC | $73.36 | 2025 | Wegovy |
| Regeneron Healthcare Solutions, INC. | $71.06 | 2025 | Dupixent |
| Gilead Sciences, INC. | $46.70 | 2024-2025 | |
| Aimmune Therapeutics, INC. | $26.49 | 2025 | Vowst |
| Conmed Corporation | $21.20 | 2024 | Conmed Dilation, Conmed Polypectomy |
| Lilly USA, LLC | $20.45 | 2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $18.54 | 2024 | Voquezna |
| Tersera Therapeutics LLC | $18.07 | 2025 | Quzyttir |
| Intercept Pharmaceuticals, INC. | $15.35 | 2024 | |
| Eisai INC. | $14.10 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rahul Kataria listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.